Purpose: To study whether anti-vascular endothelial growth factor (VEGF) therapy improves visual acuity (VA) in patients with exudative age-related macular degeneration (AMD) complicated with retinal pigment epithelium (RPE) tears.
Methods: Retrospective case-control series. Group I (control group) included 9 patients with RPE tears that received no treatment, and group II (intervention group) incorporated 12 patients treated with anti-VEGF.
Results: A statistically significant difference was found in VA between the groups from the 3rd month to the final follow-up (p = 0.034). Final VA improved in the treatment group (p = 0.015). No differences were found in central macular thickness between the groups either before or after treatment. Mean number of injections in group II was 5.75 (SD = 1.19). Most patients presented a grade 3 rip. All lesions were inactive at the end of follow-up in group II and 1 remained active in group I. The number of final atrophic/disciform scars was 6/8 in group I and 7/5 in group II.
Conclusions: RPE tears treated with antiangiogenic drugs experienced functional benefit. To the authors' knowledge, this is the first controlled series reporting effectiveness of suppression of neovascular activity with antiangiogenic treatment after RPE rip in AMD.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1159/000338730 | DOI Listing |
Expert Rev Hematol
January 2025
Nishtar Medical University and Hospital, Multan, Pakistan.
Background: To compare plateletcount (PC), mean platelet volume (MPV), and platelet distribution width (PDW)between women with preeclampsia (PE) and normotensive pregnant women, andevaluate their effectiveness as predictors of PE.
Research Design Andmethods: This cross-sectionalstudy at Nishtar Hospital, Multan, included 141 women: 74 normotensive and 67preeclamptic. Data was collected using an automated hematology analyzer andanalyzed with SPSS version 26 and ROC curves.
J Sports Sci
January 2025
Department of Tourism, Sport and Society, Lincoln University, Christchurch, New Zealand.
This study investigates the effectiveness of blood flow restriction (BFR) training in maintaining athletic performance during a taper phase in basketball players. The taper phase aims to reduce external load while maintaining training intensity. Seventeen experienced basketball players were randomised into two groups: a placebo group ( = 8, 22.
View Article and Find Full Text PDFClin Trials
January 2025
Department of Biostatistics, University of Florida, Gainesville, FL, USA.
Introduction: The sequential parallel comparison design has emerged as a valuable tool in clinical trials with high placebo response rates. To further enhance its efficiency and effectiveness, adaptive strategies, such as sample size adjustment and allocation ratio modification can be employed.
Methods: We compared the performance of Jennison and Turnbull's method and the Promising Zone approach for sample size adjustment in a two-phase sequential parallel comparison design study.
Background/aims: Certain sociodemographic groups are routinely underrepresented in clinical trials, limiting generalisability. Here, we describe the extent to which enriched enrolment approaches yielded a diverse trial population enriched for older age in a randomised controlled trial of a blood-based multi-cancer early detection test (NCT05611632).
Methods: Participants aged 50-77 years were recruited from eight Cancer Alliance regions in England.
Ocul Immunol Inflamm
January 2025
Ocular Oncology Service, Institute of Oncology, Tecnologico de Monterrey, Monterrey, Mexico.
Purpose: To present the case of a young patient with BRAF V600E-mutant cutaneous melanoma who developed bilateral choroidal metastases complicated by neovascular glaucoma (NVG) in both eyes following the interruption of nivolumab therapy.
Methods: A 28-year-old female with primary cutaneous melanoma of the left hand underwent surgical resection and adjuvant nivolumab. Immunotherapy was discontinued due to immune-related acute interstitial nephritis.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!